Overview

* Ironwood Q3 2025 revenue rises 33% yr/yr, beating analyst expectations

* Adjusted EBITDA for Q3 2025 beats estimates, reflecting strong operational performance

* Company raises full-year 2025 guidance for LINZESS U.S. net sales and adjusted EBITDA

Outlook

* Ironwood raises 2025 LINZESS U.S. net sales guidance to $860 - $890 mln

* Company increases 2025 total revenue guidance to $290 - $310 mln

* Ironwood expects 2025 adjusted EBITDA to exceed $135 mln

Result Drivers

* LINZESS DEMAND - Strong prescription demand growth and improved net pricing drove Q3 results, according to CEO Tom McCourt

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $122.06 $74.70

Revenue mln mln (5

Analysts

)

Q3 EPS $0.23

Q3 Beat $41.93 $19.80

Adjusted mln mln (2

Net Analysts

Income )

Q3 Net $40.08

Income mln

Q3 Beat $81.81 $35.60

Adjusted mln mln (3

EBITDA Analysts

)

Q3 Basic $0.25

EPS

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy."

* Wall Street's median 12-month price target for Ironwood Pharmaceuticals Inc ( IRWD ) is $1.00, about 92% below its November 7 closing price of $1.92

* The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 5 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)